REFCAR

Reference table for FDA-approved CAR T-cell products

CAR-T product	Disease	Study	Publication	ORR	CR	Median DOR	1-year PFS	CRS	G3+ CRS	ICANS	G3+ ICANS	Median FU	Comments
YESCARTA®	3L+ Large B cell lymphoma	ZUMA-1	Locke et al, The Lancet Oncology, 2019	83%	58%	11m	70%	93%*	11%	64%*	32%	27m	*from prior report in NEJM Neelapu et al 2017
YESCARTA®	3L+ Indolent (FL, MZL)	ZUMA-5	Jacobson et al, The Lancet, 2021	96%	74%	11m	50%	82%	7%	59%	19%	19m
YESCARTA®	2L Large B cell lymphoma	ZUMA-7	Locke et al, NEJM, 2022	83% (CAR) vs 50% (SOC)	65% (CAR) vs 32% (SOC)	Not reported	~55% (CAR) vs ~30% (SOC)	92%	6%	60%	21%	25m	Toxicity outcomes in CAR arm only
BREYANZI®	3L+ Large B cell lymphoma	TRANSCEND NHL	Abramson et al, The Lancet, 2020	73%	53%	Not reached	40%	42%	2%	30%	10%
BREYANZI®	2L Large B cell lymphoma	TRANSFORM	Kamdar et al, The Lancet, 2020	86% (CAR) vs 48% (SOC)	66% (CAR) vs 39% (SOC)	Not reached (CAR) vs 14.5m (SOC) - in CR pts	53% (CAR) vs 34% (SOC)	49%	1%	12%	4%	6m	Toxicity outcomes in CAR arm only
BREYANZI®	3L CLL/SLL	TRANSCEND CLL 004	Siddiqi et al, The Lancet, 2023	45%	20%	35m	~50%	85%	9%	45%	19%	20m	uMRD rate in blood and marrow: 63% and 59%, respectively
TECARTUS®	R/R Mantle cell lymphoma	ZUMA-2	Wang et al, NEJM, 2020	93%	67%	Not reached	40%	91%	15%	63%	31%
TECARTUS®	R/R B-ALL	ZUMA-3	Shah et al, The Lancet		71%	13m	~50%	89%	24%	60%	25%	16m	*allo-HCT post CAR-T in 18%
KYMRIAH®	3L+ Large B cell lymphoma	JULIET	Schuster et al NEJM, 2019	52%	40%	Not reached	~40%	58%	22%*	21%	12%	28m	*Per PENN scale
KYMRIAH®	3L+ Follicular lymphoma	ELARA	Fowler et al. Nat Med, 2022	86%	69%	Not reached	67%	49%	0%	37%	3%		CRS per Lee scale, ICANS per CTCAE
ABECMA®	4L+ Multiple myeloma	KarMMa	Munshi et al, NEJM, 2021	73%	33%	11m*	~40%	84%	5%	18%	3%		*per 5/19/21 BMS press release
CARVYKTI®	4L+ Multiple myeloma	CARTITUDE-1	Berdeja et al, NEJM 2021	97%	67%	Not reached	77%	95%	4%	21%	9%	12m

~ estimated from the Kaplan-Meier curves (not directly reported in the publication)